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Background. Tumour characteristics are the most important prognostic factors in breast cancer. Patient-related factors such as
young age at diagnosis, obesity, and smoking behaviour may also modify disease outcome. Due to the absence of a unique
definition for “young age breast cancer” and the resulting variation in disease management, findings on the association between
young age and prognosis of breast cancer are controversial. Methods. This study included 1500 patients with a primary diagnosis
of breast cancer in six Iranian hospitals from 5 provinces. We modelled the relative excess risk (RER) of breast cancer death to age
at diagnosis and tumour characteristics. Results. Excess risks of death were observed for stage IV disease and poorly diﬀerentiated
tumours: RER of 4.3 (95% CI: 1.05–17.65) and 3.4 (95% CI: 1.17–9.87), respectively. “Older” patients, particularly those aged
50 and over, presented more often with advanced and poorly diﬀerentiated tumours (P = 0.001). After adjustment for stage,
histological grade, Her-2 expression, estrogen and progesterone receptors, and place of residency, breast cancer mortality was not
significantly diﬀerent across age groups. Conclusion. We conclude that there is no prognostic eﬀect of age at diagnosis of breast
cancer among breast cancer patients treated at cancer centres in diﬀerent parts of Iran; young and relatively old women have similar
risks of dying from breast cancer.
1. Background
Tumour characteristics such as size, tumour grade, receptor
status, and lymph node involvement are known to be the
most important prognostic factors in breast cancer [1, 2].
Patient-related factors such as obesity, cigarette smoking,
alcohol consumption, and age may modify disease outcome
[3–6]. The prognostic value of age at diagnosis is particularly
controversial due to the fact that there is no worldwide
consensus on age boundaries for the definition of “young”
age breast cancer. In the literature, the cut-oﬀ point of young
age varies and has been set at age, 30, 35, 40, and 45. As a
consequence, variation in disease management may occur in
patients of similar age.
Most reports on risks of young age breast cancer come
from western countries with small proportions of young
patients [7–13]. Some of these studies suggested that negative
prognostic influence of young age is thought to be related
to the less favourable tumour characteristics as presented by
young women. However, neither the worse influence in its
own nor the factors that have been suggested to explain the
influence of young age are universally accepted.
In developing countries, the shorter life expectancy leads
to relatively large numbers of young age breast cancer,
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relative frequencies ranging from 10% to 30% of the total
number of breast cancer cases, depending on diﬀerent age
definitions [14]. Despite this high frequency of young age
breast cancer, little has been reported on the prognostic
influence of young age on breast cancer prognosis in these
countries. The few studies available have mostly presented
either no adverse eﬀect or even a better survival for those
diagnosed at a young age [15–17].
In Iran, the average age of diagnosis of female breast
cancer is approximately 15 years lower than that reported in
western populations [15, 18]. Given the increasing trend in
breast cancer incidence [19] and the large number of young
age cases in Iran, it is crucial to gain a better understanding
of disease characteristics and clinical consequences of young
age breast cancer in order to guide health policy makers on
resource allocation, diagnosis, and treatment facilities. In this
respect, our study examines the relative survival of breast
cancer using a relatively large series of patients from diﬀerent
regions of Iran.
2. Methods
This study used reviews of hospital records of female breast
cancer patients in Iran. In order to have a representative
sample from Iran, we selected 5 out of 30 provinces in
diﬀerent geographical regions. Data were collected for a
sample of 1500 patients from cancer referral centres located
in these regions. In Iran, the Ministry of Health issued
general privacy rules for health care and research. On top of
that, most hospitals have internal rules on privacy and ethics.
Accessibility to medical records in this study was approved
by the Ministry of Health and the general manager of each
hospital.
2.1. Patient Recruitment. We used a multistage sampling
procedure to select our study population. First, we selected
5 provinces with at least one cancer excellence centre. The
selection was also based on availability of data for the period
1999–2001 and feasibility considering our time and budget
constraints. In Iran, all hospitals are using paper-based
medical records system. All medical records of breast cancer
patients diagnosed in the period 1999–2001 were identified
with the help of medical record administrative staﬀ. In the
next stage, we randomly selected a patient record from the
list as a starting point and then chose a specified number
of consecutive female breast cancer patients in each centre.
If a certain record was not available at the time of study at
the archives of the medical centre, it was replaced by the
following record number (case). In case of incompleteness
of medical records, we searched for additional data via
private clinics or outpatient clinics where patients are usually
referred to after primary treatment in the hospital. We also
asked additional information from the patients themselves
when we contacted them (or their family) for followup.
2.2. Data Collection. Recorded data include patient and
tumour characteristics coded according to the Interna-
tional Classification of Diseases for Oncology (ICD-O).
Tumour histology was grouped into invasive ductal, lob-
ular, medullary, and other types of carcinoma. Tumour
stage was classified into 4 categories according to the
TNM classification of the 5th edition of the American
Joint Committee on Cancer Classification (AJCC): stage I
(T1N0M0), stage II (T0-1N1M0, T2N0-1M0, T3N0M0), stage
III (T0–2N2M0, T3N1-2 M0, T4N0–2M0, T0–4N3M0), and stage
IV (T0–4N0–3M1). Histological grade was classified into 3
classes from grade 1 to 3 based on the Nottingham grading
system. Hormone receptor status was extracted from the
medical records and pathology reports. Expression of human
epidermal growth factor receptor 2 (Her-2) was assessed
based on the result of immunohistochemistry (IHC) and
graded as negative or positive Her-2 (cut-oﬀ point ≤2+).
Detailed information on treatment and type of surgery was
only available for a minority of the patients and was therefore
not considered in the analyses.
We stratified all patients into 4 age groups: <35, 35–49,
50–64, and 65+ years. Age 35 was considered as cut-oﬀ point
to define young age breast cancer. Followup was obtained
for at least five years after diagnosis until March 20, 2008.
Followup data were collected through death certificates in
the medical records of the hospitals and private clinics or
through short visits/telephone interviews with patients or
their relatives after obtaining verbal consent. Survival time
was considered as the time from diagnosis until death (as
event). Patients alive at the end of study or lost to followup
were censored in the analysis.
2.3. Data Analysis. Despite our eﬀorts to minimize missing
data, we still faced many missing values in our dataset. In
this regard, depending on the type (missing at random) and
frequency of missing values (with an arbitrary boundary
of 20%), we predicted those values using a conditional
imputation technique. To do so, we used the data from all
patients without missing values on the variable to develop
a multivariable prediction model. Using logistic regression
analysis, we predict the most likely value of missing values
for grade and Her-2 expression conditional on the values of
other variables such as year of diagnosis, age at diagnosis,
outcome, estrogen (ER) and progesterone receptor status
(PR), and place of residency. This procedure yielded 680
and 868 imputed values for “grade” and “Her-2 expression,”
respectively.
Overall survival rates were estimated using the Kaplan-
Meier method. The relative survival ratio (RSR) was mod-
elled using the calculated survival from the current study
population and the expected survival derived from the life
table of the general female population in Iran (including 5-
year intervals from 0 to 80+ years) in 2004 using the “Ederer-
II” method [20]. The expected hazard is estimated from
external age-, sex- and period-matched data from the general
population. This model is known as an additive hazard
model or a relative survival model since it can be written
as S(t; z) = S∗(t; z)∗r(t; z), where S(t; z), S∗(t; z), and r(t; z)
represent the cumulative observed, expected, and relative
survival. The hazards are assumed to be constant within
followup times (with the length of 1 year). The basic relative
survival model introduced by Este`ve et al. is therefore written
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as: λ(x) = λ∗(x) + exp(xβ) [21], where x denotes the
covariates vector such as year of follow-up, province (place of
residency), disease stage, grade, ER, PR andHer-2 status. The
exponentiated parameter estimates have an interpretation
as excess hazard ratios, which are known as relative excess
risks (RERs). An excess hazard ratio of, for example, 2.0 for
patients having stage 2 compared to patients with stage 1
implies that the excess hazards associated with a diagnosis
of breast cancer is 100 percent higher for stage 2 patients
than stage 1 patients. SAS Macro Program version 7.0 (Lexis
macro for splitting person-time) was used for all statistical
analyses.
3. Results
3.1. Patient Characteristics. Characteristics of the study pop-
ulation and tumours are summarized in Tables 1 and 2. Of
the 1500 patients, the mean age at diagnosis was 46.0 + 12.0
(SD) years. The percentages of patients in the age groups of
<35, 35–49, 50–64, and 65+ year were 14.4%, 49.6%, 27.7%,
and 8.3%, respectively. Family history (1st and 2nd degree
relatives) of breast cancer was positive among less than 5%
of all patients.
Tumour histology types were equally distributed over the
age groups (P value: 0.20). Proportions of other tumour
characteristics diﬀered between the age groups. Tumour
characteristics of patients aged <35 were more or less
similar to those at age 35–49 and 50–64 years. However,
patients aged <35 more often had tumours with favourable
characteristics compared to patients aged 65 and more (P
value: <0.01). Lower grade tumours were more frequent
among patients <35 years. More than 50% of all age groups
had a tumour size of 2–5 cm. Women under age 50 had
smaller tumour sizes compared to elderly patients (P value:
0.04).
3.2. Survival Analysis. At the end of the followup period,
380 women had died (25.3% of all women in the study).
We were not able to find disease outcome for more than
16% of all patients (loss to followup). This percentage was
17%, 18%, 15%, and 6% for the youngest to the oldest age
groups. Patients were followed for a minimum of 2 and a
maximum of 96 months from diagnosis until death, loss to
followup, or end of study. The overall 5-year Kaplan-Meier
survival rate for the study population was 72% (95% CI:
69%–74%). In Figure 1, the unadjusted survival rates for the
four age groups at diagnosis are presented. The observed 5-
year survival ratios for the patients from the five provinces
varied from 67% to 79%.
Table 3 presents the observed and expected 5-year
survival and RSR for women in the four age groups. The
5-year RSR of young patients (age < 35) was similar to
the RSRs of those aged 35–49 and 50–64. The RSR of the
oldest patients (aged 65 and over) was better compared to all
younger age groups (RSR: 1.23).
Table 4 shows the crude and adjusted RER of breast
cancer death, using the imputed and nonimputed data. In the
univariable analysis of hormonal receptor status, age, stage,
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Figure 1: Kaplan-Meier survival curves for breast cancer patients in
Iran for four age groups at diagnosis.
grade, and Her-2, tumour stage, grade and Her-2 status were
related to breast cancer death. In the multivariable analysis,
depending on the missing values, grade and Her-2 status
remained significant in imputed dataset. However, without
imputation, none of included variables remained significant
(Table 4, middle column). In particular, age at diagnosis
was not associated with excess risk of death neither in the
univariable nor in the full model.
4. Discussion
After adjustment for diﬀerences in tumour characteristics
between age groups, we found no evidence of an independent
eﬀect of age at diagnosis on the risk of dying from breast
cancer. To the best of our knowledge, this is the first report
of breast cancer survival in diﬀerent regions in Iran. The
large study population and the inclusion of relative survival
and excess risk statistics are advantages over other published
studies from Iran so far [22–24].
Our finding on the absence of any impact of age at
diagnosis on breast cancer survival is in agreement with
the findings from some other studies especially those from
Asian populations [25–27]. Other studies, however, mostly
those conducted in western countries, found that age at
presentation does influence the outcome of breast cancer
and suggest that age should be taken into consideration
for patient management [7, 9, 11]. They demonstrated that
breast cancer in young women is less favourable because
of advanced stage, tumour aggressiveness, and negative
hormone-receptor status. However, this predictive role of
age at diagnosis is not universally found and accepted
[25, 28, 29]. In a large cohort study conducted in Swedish
women, the less favourable survival of young age breast
cancer was more predominant in those diagnosed with early
stage breast cancer [7]. We, however, found no diﬀerences
in survival between the age groups in the stage-stratified
analyses (results are not shown). This may be attributed to
the low frequency of early stage tumours in our study due to
low awareness of breast cancer and lack of a national early
detection program in Iran.
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Table 1: Demographic characteristics of 1500 Iranian patients with breast cancer, diagnosed in 1999–2001, by age category.
<35 yr
n = 216
35–49 yr
n = 745
50–64 yr
n = 415
65+ yr
n = 124
N (%) N (%) N (%) N (%)
Province
Tehran 71 (11.8) 296 (49.8) 186 (30.8) 48 (8.0)
Mazndaran 37 (18.4) 96 (47.8) 55 (27.4) 13 (6.5)
Fars 34 (17.0) 102 (51.0) 47 (23.5) 17 (8.5)
Khuzestan 42 (21.1) 82 (41.2) 54 (27.1) 21 (10.6)
Esfahan 32 (10.7) 169 (56.3) 74 (24.7) 25 (8.3)
Education
Illiterate 22 (10.2) 265 (35.6) 275 (66.3) 91 (73.4)
Primary and secondary 57 (26.4) 135 (18.1) 66 (15.9) 13 (10.5)
High school 104 (48.2) 285 (38.3) 59 (14.2) 17 (13.7)
College/university 33 (15.3) 60 (8.0) 15 (3.6) 3 (2.4)
Job status
Paid job 37 (17.1) 151 (20.3) 57 (13.7) 15 (12.1)
Family history
Positive 8 (3.7) 28 (3.8) 14 (3.4) 1 (0.8)
In addition, some believe that early age of breast cancer
(which is common in developing countries) could be asso-
ciated with familial (hereditary) breast cancer with a rather
diﬀerent biology [30]. Hereditary breast cancer is associated
with mutations in genes such as BRCA1 and BRCA2 and
accounts for 5%–10% of all breast cancer. Contrary to what
we expected, only 5% of our selected patients presented a
positive family history among their first or second degree
relatives. This low frequency may be due to missing data
regarding family history in the medical records which makes
it impossible to distinguish a negative family history status
from unavailability of data. Previous studies have reported
a frequency of 3% to more than 10% of positive family
history, without significant diﬀerences between young and
older patients, in Iran so far [31, 32].
In most reports, the classical prognostic factors such as
disease stage, grade, and Her-2 status are good predictors
of breast cancer survival [2, 3, 7]. Some of these factors,
for example, tumour stage could reflect diﬀerences in
socioeconomic status (SES), health care accessibility and
early detection facilities, while others are more related to
variation in tumour biology. Although our results showed
a clear trend of tumour stage on RER, none of them were
statistically significant. We tried to make it clear by analysing
separate parameter of tumour stage including tumour
size, metastases, and nodal involvement. Despite significant
individual eﬀect of each parameter on RER, their eﬀect
became nonsignificant in multivariate analysis. Similar non-
significant eﬀect of tumour stage on breast cancer outcome,
either recurrence or death, has been reported by two studies
with smaller sample size conducted in Iran [22, 33].
We found that tumours in older patients are more
aggressive than in younger patients, which might be linked
to genetic or endocrine factors [34, 35]. Also, positivity of
HER-2 was higher than reported average. This could be
partly explained by a lower cut-oﬀ point considering HER-
2 positivity in Iran in that period. Mylonas and cowork-
ers hypothesize that the HER-2 overexpression in tumors
originated from atypical ductal hyperplasia (ADH) is more
prominent than when derived from ductal carcinoma in situ
(DCIS) [36]. Available data indicate that the percentage of
DCIS in Iranian patients is very low (approximately 1.5%)
[37].
In our series, younger patients presented more often with
Her-2 negative tumours. This is in contrast with a previous
report on Iranian patients that reported a higher frequency
of Her-2 negative tumours in older patients from the capital
city of Tehran [38]. This discrepancy may be partially related
to changes in laboratory techniques over time and diﬀerences
between a single-centre versus a multicentre study such as
ours.
Considering the more advanced and aggressive tumours
occurring in older patients, it seems that the relative survival
of patients aged 65 and over should be worse. However,
we noticed that the relative survival ratio of older patients
was higher compared to that in the younger age groups.
The central issue in relative survival is the comparability of
the cohort and general population and the calculation of
the expected survival. The “good” relative survival among
patients aged 65+ year could be related to incomparability
between elderly breast cancer patients and the general elderly
population in Iran. As breast cancer mostly aﬀects women
of higher SES, old patients registered at hospitals are more
likely to belong to higher SES levels and are less likely to
have serious comorbidity than their peers and may have
lower background mortality [39]. If this is true, then relative
survival will be overestimated and artificially high. Therefore,
the fact that elderly patients with breast cancer have a poorer
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Table 2: Tumour characteristics of breast cancer patients in Iran diagnosed in the period of 1999–2001.
Age at diagnosis
Total (n = 1500) P value<35
n = 216
35–49
n = 745
50–64
n = 415
65+
n = 124
Tumour size (cm)
<2 cm
2–5 cm
>5 cm
Missing
32 (14.8)
121 (56.0)
37 (17.1)
26 (12.1)
129 (17.3)
404 (54.2)
137 (18.4)
75 (10.1)
60 (14.5)
232 (55.9)
87 (21.0)
36 (8.6)
16 (12.9)
64 (15.6)
36 (29.0)
8 (6.5)
237 (15.8)
821 (54.7)
297 (19.8)
145 (9.7)
0.04∗
Lymph node
involvement
0 node
1–3 nodes
4–9 nodes
10+ nodes
Missing
46 (21.3)
50 (23.2)
80 (37.0)
15 (6.9)
25 (11.6)
135 (18.1)
169 (22.7)
320 (43.0)
33 (4.4)
88 (11.8)
67 (16.2)
106 (25.6)
167 (40.2)
35 (8.4)
40 (9.6)
21 (16.9)
20 (16.1)
45 (36.3)
29 (23.4)
9 (7.3)
269 (17.9)
345 (23.0)
612 (40.8)
112 (7.5)
162 (10.8)
0.00∗
Distant metastases
No
Yes
Missing
160 (74.1)
27 (12.5)
29 (13.4)
551 (74.0)
104 (14.0)
90 (12.0)
311 (75.0)
61 (14.7)
43 (10.3)
75 (60.5)
32 (25.8)
17 (13.7)
1097 (73.2)
224 (14.9)
179 (11.9)
0.01∗
Grade
Grade 1
Grade 2
Grade 3
Missing
14 (6.5)
85 (39.4)
26 (12.0)
91 (42.1)
44 (5.9)
303 (40.7)
60 (8.0)
338 (45.4)
18 (4.3)
161 (38.8)
46 (11.1)
190 (45.8)
5 (4.0)
21 (16.9)
37 (29.9)
61 (49.2)
81 (5.4)
570 (38.0)
169 (11.3)
680 (45.3)
0.00∗
Estrogens receptor
Negative
Positive
Unknown/not done
61 (28.2)
119 (55.1)
36 (16.7)
185 (24.8)
420 (56.4)
140 (18.8)
89 (21.4)
225 (54.2)
101 (24.3)
30 (24.2)
73 (58.9)
21 (16.9)
365 (24%)
837 (56%)
298 (20%)
0.14
Progesterone receptor
Negative
Positive
Unknown/not done
53 (24.5)
128 (59.3)
35 (16.2)
226 (30.3)
381 (51.1)
138 (18.5)
121 (29.2)
188 (45.3)
106 (25.5)
37 (29.8)
66 (53.2)
21 (16.9)
437 (29%)
763 (51%)
300 (20%)
0.00∗
Her-2 expression
Positive
Negative
Unknown/not done
71 (32.9)
32 (14.8)
113 (52.3)
190 (25.5)
118 (15.8)
437 (58.7)
95 (22.9)
73 (17.6)
247 (59.5)
31 (25.0)
22 (17.7)
71 (57.3)
245 (16.3)
387 (25.8)
868 (57.9)
0.00∗
Tumour subtype
Ductal
Lobular
Medullary
Other
190 (88.0)
9 (4.2)
16 (7.4)
1 (0.5)
658 (88.3)
32 (4.3)
43 (5.8)
12 (1.6)
368 (88.7)
27 (6.5)
16 (3.9)
4 (1.0)
112 (90.3)
8 (6.5)
3 (2.4)
1 (0.8)
1328 (87.0)
76 (4.9)
78 (4.5)
18 (1.2)
0.20
∗
Significant at α = 0.05.
Table 3: Observed, expected, and relative survival rate (RSR) of breast cancer patients in Iran, diagnosed in 1999–2001.
Age at diagnosis Number of patients (death)
5-year survival rate
RSR (95% CI)
Observed Expected
<35 216 (32) 83.4 97.0 0.86 (0.80–0.91)
35–49 745 (130) 81.0 93.0 0.86 (0.83–0.89)
50–64 415 (136) 64.0 76.0 0.85 (0.78–0.91)
65+ 124 (82) 39.0 32.0 1.20 (0.92–1.53)§
§
Excluding patients over 74 years.
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Table 4: Relative excess risk of breast cancer death in Iranian women diagnosed in 1999–2001.
Univariate Multivariate
Factors RER 95% CI
Adjusted RER (95% CI)
(before imputation)
Adjusted RER
(after imputation)
(95% CI)
Age at presentation
<35 1 Reference 1 1
35–49 1.0 (0.64–1.68) 1.2 (0.46–3.13) 1.1 (0.66–1.78)
50–64 1.0 (0.56–1.92) 1.7 (0.62–5.03) 1.1 (0.61–1.92)
65+ 0© — 1.1 (0.12–10.23) 0.5 (0.11–2.65)
TNM-stage
I 1 Reference 1 1
II 2.0 (0.50–8.04) 2.1 (0.35–29.78) 1.2 (0.42–3.74)
III 2.4 (0.60–10.23) 3.2 (0.21–22.32) 1.3 (0.41–4.02)
IV 4.3 (1.10–17.63)∗ 6.5 (0.64–64.83) 1.7 (0.52–5.22)
Grade (imputed) (Nonimputed) (680 imputed values)
Grade 1 1 Reference 1 1
Grade 2 2.2 (0.66–7.31) 3.8 (0.47– 30.62) 2.1 (0.67–6.45)
Grade 3 7.0 (2.10–23.10)∗ 6.6 (0.49–88.39) 8.4 (2.63–27.16)∗
Estrogens receptor
Negative 1 Reference 1 1
Positive/unknown 0.8 (0.50–1.18) 0.9 (0.38–2.23) 0.7 (0.38–1.12)
Progesterone receptor
Negative 1 Reference 1 1
Positive/unknown 0.8 (0.55–1.28) 0.7 (0.30–1.64) 1.1 (0.65–1.85)
Her-2 expression
(imputed)
(Nonimputed) (868 imputed values)
Positive 1 Reference 1 1
Negative 0.5 (1.30–2.74)∗ 0.5 (0.24–1.00) 0.4 (0.25–0.57)∗

Adjusted for all other variables in this table (full model) and place of residency.
©Relative survival from patients aged 65+ is >1, corresponding to a negative excess hazard in our model, but the model does not allow for negative excess
hazards.
∗Statistically significant at α = 0.05.
survival compared to younger patients could be masked by
the poor life expectancy of the Iranian elderly population.
Additionally, in our followup, some deaths are missed (loss
to followup cases), leading to a biased estimate of the relative
survival through biased expected survival.
In spite of our eﬀorts to trace all patients, for 16% of
our cohort, no contact information or updated outcome
information was available in the medical records. Consid-
ering the fact that poor data records is often associated
with poor care, it is likely that censored cases which were
more prevalent in the younger age group have a shorter
survival compared to cases who had complete followup. This
might cause major bias, particularly when the probability
of loss to followup depends on the outcome. In our study,
we were not able to directly specify such dependency, but
from the literature (from high-income countries) it is well
known that those patients who have a higher probability of
dying are more likely to drop out [40]. Diﬀerences in loss
to followup between diﬀerent age groups can lead to bias
as the patients who are younger (or older) might be more
(or less) likely to die from breast cancer. Variation in loss
to followup may be common not only due to death but also
due to a patient’s behaviour with respect to changing doctors
and hospitals, especially when patients have a higher ability
to pay for the treatment in the private sector. Therefore, it
is also possible that those lost to followup may have a better
survival. Considering these diﬀerent scenarios, our estimated
survival should be interpreted with caution.
The lack of detailed treatment information is also a
limitation for this study and might have changed the
outcome. Because of lower socioeconomic status and lack
of knowledge of the elderly patients, for example on the
availability of systematic treatment, these women may not
receive optimal treatment. Data correlating SES and breast
cancer survival (or survival from other diseases) are scarce
in low and middle income countries. Few available data,
using diﬀerent measures of SES such as income, education,
occupation, and health insurance coverage, clearly show
strong associations between low SES and advanced disease,
delay in diagnosis, and inferior survival [41, 42]. In our
study, younger women presented with higher SES based on
education and occupational status than older women. On
International Journal of Breast Cancer 7
the one hand, they may have a higher chance to develop
breast cancer due to a more modernized life style and being
registered as breast cancer case at the excellent centre for
cancer treatment. This may hamper generalizability of our
findings to all women in Iran, as this country is highly diverse
in ethnicity and SES.
Considering the impact of the selection bias, patients
with a higher socioeconomic status (SES) may have a better
chance to be referred to and registered at a Cancer Excellent
Centre. This may favor treatment eﬀect. The selection bias
may also go in the opposite direction; patients with higher
SES may choose alternative facilities because they do not
trust (pessimistic perception) educational centres (these
Excellent Cancer Centres are usually educational hospitals).
5. Conclusion
These results indicate that age at diagnosis has no indepen-
dent eﬀect on clinical outcome of breast cancer in the group
of patients from cancer centres in a number of provinces in
Iran. Younger women with breast cancer do not have a worse
survival than those diagnosed at a later age. We demonstrate
that tumour characteristics are the only relevant factors when
deciding on disease management and treatment intensity. As
breast cancer in Iran occurs at earlier age, there is a need
to reevaluate the current priority given to breast cancer as
a health problem in Iran. Moreover, the higher incidence of
advanced tumours in both young and older patients of our
study may provide additional support for the need to start a
national control program for breast cancer.
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